Showing posts with label Program. Show all posts
Showing posts with label Program. Show all posts

Saturday, December 18, 2010

Computer-based Program May Help Relieve Some ADHD Symptoms In Children


Main Category: ADHD
Also Included In: Psychology / Psychiatry;??Pediatrics / Children's Health;??IT / Internet / E-mail
Article Date: 10 Dec 2010 - 5:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend ? printer icon printer friendly ? write icon opinions ?
not yet rated4 stars
An intensive, five-week working memory training program shows promise in relieving some of the symptoms of attention deficit hyperactivity disorder in children, a new study suggests.

Researchers found significant changes for students who completed the program in areas such as attention, ADHD symptoms, planning and organization, initiating tasks, and working memory.

"This program really seemed to make a difference for many of the children with ADHD," said Steven Beck, co-author of the study an associate professor of psychology at Ohio State University.

"It is not going to replace medication, but it could be a useful complementary therapy."

Beck conducted the study with Christine Hanson and Synthia Puffenberger, graduate students in psychology at Ohio State. Their findings are published in the November/December 2010 issue of the Journal of Clinical Child & Adolescent Psychology.

The researchers tested software developed by a Swedish company called Cogmed, in conjunction with the Karolinska Institute, a medical university in Stockholm.

The software is designed to improve one of the major deficiencies found in people with ADHD working memory.

Working memory is the ability to hold onto information long enough to achieve a goal. For example, you have to remember a phone number long enough for you to dial it. Students have to remember the passage of a book they just read, in order to understand what they're currently reading.

"Working memory is critical in everyday life, and certainly for academic success, but it is one of the things that is very difficult for children with ADHD," Hanson said.

The study involved 52 students, aged 7 to 17, who attended a private school in Columbus that serves children with learning disabilities, many of whom also have an ADHD diagnoses. All the children used the software in their homes, under the supervision of their parents and the researchers.

The software includes a set of 25 exercises that students had to complete within 5 to 6 weeks. Each session is 30 to 40 minutes long. The exercises are in a computer-game format and are designed to help students improve their working memory. For example, in one exercise a robot will speak numbers in a certain order, and the student has to click on the numbers the robot spoke, on the computer screen, in the opposite order.

"At first the kids love it, because it is like a game," Puffenberger said. "But the software has an algorithm built in that makes the exercises harder as the students get better. So the children are always challenged."

Half the students participated at the beginning of the study. The other half were wait-listed, and completed the software program after the others were finished.

Parents and teachers of the participating students completed measures of the children's ADHD symptoms and working memory before the intervention, one month after treatment, and four months after treatment.

Results showed that parents generally rated their children as improving on inattention, overall number of ADHD symptoms, working memory, planning and organization and in initiating tasks. These changes were evident both immediately after treatment and four months later.

On individual measures, between one-fourth and one-third of the children showed clinically significant progress in other words, enough progress to be easily visible to their parents.

The teacher ratings, while pointed in the direction of improvement, were not strong enough to be statistically significant in this study. That's not surprising, Beck said, because very few treatment studies ever find significance among teacher measures.

"Teachers only see the kids for a few hours a day and they are dealing with a lot of other children at the same time. It would be difficult for them to see changes," Beck said.

Beck said this is the first published study they know of testing this software in the United States. One of the strengths of the study is that it used a very typical sample of children with ADHD other studies in Sweden had excluded children who were on medication.

"Most kids with ADHD are on some kind of medication, so it helps to know how this intervention works in these cases," he said.

In this sample, 60 percent of the students were on medication. The results showed the program was equally effective regardless of whether they were on medication or not.

"Medication for ADHD does not help directly with working memory, and the training program does, so it can be useful," Beck said.

"One of the encouraging findings is that parents reported even ADHD symptoms improved after the program, and that isn't the focus. This program is focused on improving working memory."

Beck said they can't say for sure how the program works to help kids with ADHD. But it seems that children are learning how to focus and how to use their working memory on everyday tasks, and they are able to use that knowledge at school and home.

One possible criticism of the study could be that it relies on parental reports, and the parents may be biased.

"That's true, but it is also the parents who are observing the kids day in and day out, and they are the ones who would be most likely to observe any changes that occur," Beck said.

The researchers plan on extending the work by using more objective measures of children's progress after using the program.

Two other co-authors of the study were William Benninger, an adjunct assistant professor of psychology at Ohio State, and Kristen Benninger, a medical student at the University of Toledo.

Beck, Hanson and Puffenberger have no financial interest in the company that makes the software. William Benninger does have an interest, but was not involved in the collection of the data.

Source: Ohio State University

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:






View the original article here

Thursday, December 16, 2010

Computer-based program may help relieve some ADHD symptoms in children

ScienceDaily (Dec. 11, 2010) ? An intensive, five-week working memory training program shows promise in relieving some of the symptoms of attention deficit hyperactivity disorder in children, a new study suggests.

Researchers found significant changes for students who completed the program in areas such as attention, ADHD symptoms, planning and organization, initiating tasks, and working memory.

"This program really seemed to make a difference for many of the children with ADHD," said Steven Beck, co-author of the study an associate professor of psychology at Ohio State University.

"It is not going to replace medication, but it could be a useful complementary therapy."

Beck conducted the study with Christine Hanson and Synthia Puffenberger, graduate students in psychology at Ohio State. Their findings are published in the November/December 2010 issue of the Journal of Clinical Child & Adolescent Psychology.

The researchers tested software developed by a Swedish company called Cogmed, in conjunction with the Karolinska Institute, a medical university in Stockholm.

The software is designed to improve one of the major deficiencies found in people with ADHD -- working memory.

Working memory is the ability to hold onto information long enough to achieve a goal. For example, you have to remember a phone number long enough for you to dial it. Students have to remember the passage of a book they just read, in order to understand what they're currently reading.

"Working memory is critical in everyday life, and certainly for academic success, but it is one of the things that is very difficult for children with ADHD," Hanson said.

The study involved 52 students, aged 7 to 17, who attended a private school in Columbus that serves children with learning disabilities, many of whom also have an ADHD diagnoses. All the children used the software in their homes, under the supervision of their parents and the researchers.

The software includes a set of 25 exercises that students had to complete within 5 to 6 weeks. Each session is 30 to 40 minutes long. The exercises are in a computer-game format and are designed to help students improve their working memory. For example, in one exercise a robot will speak numbers in a certain order, and the student has to click on the numbers the robot spoke, on the computer screen, in the opposite order.

"At first the kids love it, because it is like a game," Puffenberger said. "But the software has an algorithm built in that makes the exercises harder as the students get better. So the children are always challenged."

Half the students participated at the beginning of the study. The other half were wait-listed, and completed the software program after the others were finished.

Parents and teachers of the participating students completed measures of the children's ADHD symptoms and working memory before the intervention, one month after treatment, and four months after treatment.

Results showed that parents generally rated their children as improving on inattention, overall number of ADHD symptoms, working memory, planning and organization and in initiating tasks. These changes were evident both immediately after treatment and four months later.

On individual measures, between one-fourth and one-third of the children showed clinically significant progress -- in other words, enough progress to be easily visible to their parents.

The teacher ratings, while pointed in the direction of improvement, were not strong enough to be statistically significant in this study. That's not surprising, Beck said, because very few treatment studies ever find significance among teacher measures.

"Teachers only see the kids for a few hours a day and they are dealing with a lot of other children at the same time. It would be difficult for them to see changes," Beck said.

Beck said this is the first published study they know of testing this software in the United States. One of the strengths of the study is that it used a very typical sample of children with ADHD -- other studies in Sweden had excluded children who were on medication.

"Most kids with ADHD are on some kind of medication, so it helps to know how this intervention works in these cases," he said.

In this sample, 60 percent of the students were on medication. The results showed the program was equally effective regardless of whether they were on medication or not.

"Medication for ADHD does not help directly with working memory, and the training program does, so it can be useful," Beck said.

"One of the encouraging findings is that parents reported even ADHD symptoms improved after the program, and that isn't the focus. This program is focused on improving working memory."

Beck said they can't say for sure how the program works to help kids with ADHD. But it seems that children are learning how to focus and how to use their working memory on everyday tasks, and they are able to use that knowledge at school and home.

One possible criticism of the study could be that it relies on parental reports, and the parents may be biased.

"That's true, but it is also the parents who are observing the kids day in and day out, and they are the ones who would be most likely to observe any changes that occur," Beck said.

The researchers plan on extending the work by using more objective measures of children's progress after using the program.

Two other co-authors of the study were William Benninger, an adjunct assistant professor of psychology at Ohio State, and Kristen Benninger, a medical student at the University of Toledo

Beck, Hanson and Puffenberger have no financial interest in the company that makes the software. William Benninger does have an interest, but was not involved in the collection of the data.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Ohio State University. The original article was written by Jeff Grabmeier.

Journal Reference:

Steven Beck, Christine Hanson, Synthia Puffenberger, Kristen Benninger, William Benninger. A Controlled Trial of Working Memory Training for Children and Adolescents with ADHD. Journal of Clinical Child & Adolescent Psychology, 2010; 39 (6): 825 DOI: 10.1080/15374416.2010.517162

Note: If no author is given, the source is cited instead.


View the original article here

Sunday, December 5, 2010

Targacept Announces Top-Line Results Of Phase 2 Trial Of AZD1446 In Adults With ADHD And Provides Update On Status Of AZD1446 Development Program


Main Category: ADHD
Article Date: 12 Oct 2010 - 0:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend ? printer icon printer friendly ? write icon opinions ?
not yet rated3 stars
Targacept, Inc. (NASDAQ: TRGT) announced top-line results from a Phase 2 clinical trial of AZD1446 conducted by AstraZeneca in adults with attention deficit/hyperactivity disorder (ADHD). The study was one of several early clinical studies designed by AstraZeneca to obtain, in addition to safety and tolerability information, a signal of efficacy to guide dosing in potential later-stage development of AZD1446 in either or both of Alzheimer's disease and ADHD. AZD1446 is a selective modulator of the alpha4beta2 neuronal nicotinic receptor and was licensed by Targacept to AstraZeneca pursuant to a 2005 collaboration agreement.

The study was a multi-center, randomized, double-blind, placebo-controlled, cross-over trial that assessed the efficacy, safety and pharmacokinetics of two weeks of treatment with AZD1446 as compared to placebo. Each subject was classified as a user of nicotine products or a non-user of nicotine products. Non-nicotine users received placebo and two out of three oral AZD1446 dose regimens, and nicotine users received placebo and two oral AZD1446 dose regimens.

In the trial, AZD1446 did not improve core symptoms of ADHD, as compared to placebo, as measured by the primary outcome measure, the Conners' Adult ADHD Rating Scale-Investigator Rated Total ADHD Symptoms score (CAARS-INV). Based on this finding, Targacept does not expect AstraZeneca to progress AZD1446 as a treatment for ADHD. A decision by AstraZeneca as to potential future development of AZD1446 in Alzheimer's disease is expected in the coming months.

Positive results were obtained in the study on three of five tasks of the CogState computerized test battery, secondary outcome measures designed to assess important cognitive functions such as learning and memory. Non-nicotine using subjects who received 80mg of AZD1446 once daily showed an improvement on the Groton Maze Learning Task (p=0.031) and the International Shopping List Task - Immediate Recall (p=0.007). Non-nicotine using subjects who received 80mg of AZD1446 three times daily showed an improvement on the International Shopping List Task - Immediate Recall (p=0.010) and the International Shopping List Task - Delayed Recall (p=0.086). The p-values reported are not statistically adjusted for multiplicity. AZD1446 did not demonstrate similar superiority at any dose on any of these measures in the nicotine user dataset. Other secondary outcome measures of the study did not demonstrate a drug effect.

AZD1446 was generally well tolerated in the study, and no serious adverse events were reported. Further analyses of the full dataset from the trial are ongoing.

"While we are disappointed in the results on the primary outcome measure in this ADHD trial, we are encouraged by the memory and learning findings from the CogState test battery and believe they support further study of AZD1446 as a treatment for Alzheimer's disease," said J. Donald deBethizy, Ph.D., Targacept's President and Chief Executive Officer.

In addition to the trial in adults with ADHD, the AZD1446 program includes three other early clinical studies intended to inform a decision by AstraZeneca as to potential future development in Alzheimer's disease. Two of these studies have completed. In a four-week trial designed primarily to evaluate the safety and tolerability of AZD1446 when administered with donepezil, the most commonly prescribed Alzheimer's disease treatment, to Alzheimer's disease patients, AZD1446 exhibited a safety and tolerability profile acceptable for further development. As expected with a short dosing period and small number of subjects, AZD1446 did not show an effect on surrogate measures of cognition and global function in the study. In a separate trial designed to explore the effects of a single dose of AZD1446 in healthy volunteers with drug-induced cognitive impairment, pro-cognitive signals were observed on various secondary outcome measures, but neither AZD1446 nor the positive comparator donepezil demonstrated a statistically significant effect on the study's primary outcome measure. Results from a fourth trial, designed to evaluate the pharmacodynamic effect of AZD1446 and donepezil on brain response in Alzheimer's disease patients as assessed by electroencephalography (EEG), are expected early next year.

About the Phase 2 Trial in Adults with ADHD

The Phase 2 clinical trial in adults with ADHD was a double blind, placebo controlled cross-over study conducted by AstraZeneca at six sites in the United States. A total of 79 patients aged 18 to 65 years were randomized to study treatment, including 27 nicotine users and 52 non-nicotine users. Nicotine users received in random order 80mg of AZD1446 once daily, 80mg of AZD1446 three times daily and placebo, in each case for two weeks. Non-nicotine users received in random order two of the following three dosing regimens-80mg of AZD1446 once daily, 80mg of AZD1446 three times daily and 10mg AZD1446 three times daily-as well as placebo, in each case for two weeks. For both groups, consecutive dosing periods were separated by a three-week washout period, for a total study duration of twelve weeks. As a result of the cross-over design, each patient served as his or her own control.

About AZD1446

AZD1446 is a selective modulator of the alpha4beta2 neuronal nicotinic receptor. The compound was discovered by Targacept scientists as part of a now-completed research collaboration conducted with AstraZeneca under a 2005 collaboration agreement.

Source:
Targacept, Inc.

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:






View the original article here